Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL

Recruiting now · Phase 2/Phase 3

Conditions studied: Primary Central Nervous System Lymphoma

In brief

This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in elderly patients with primary central nervous system lymphoma (PCNSL).

Key facts

Study ID

NCT02836158

Run by

Navy General Hospital, Beijing

People needed

100

Starts

2010-09-01

Expected to finish

2030-12-01

Last updated by the study team

2020-09-09

Who can join

Age: 60 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Newly diagnosed histologically proven non-Hodgkin's lymphoma (NHL).

You may not qualify if…

• Involved sites other than the brain, meninges, CSF, or the eyes.
• Age less than 18 years or greater than 75 years.
• Inadequate bone marrow capacity (defined as neutrophils<1.5 ×10\^9/L, platelets <100 ×10\^9/L, and hemoglobin level< 8 g/dL).
• Known cause of immunosuppression (ie, HIV type I infection).
• Any previous malignancy.
• Creatinine clearance below 60 mL/min.
• Heart insufficiency (NYHA IIIB or IV).
• Uncontrolled infection.
• Noncompensated active pulmonary or liver disease.
• Previously treated for PCNSL, except by corticosteroids.

Where it is running

• Navy General Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.